Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Go back to Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder| (NASDAQ: VTGN) | Delayed: 0.66 +0.03 (4.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.63 | 52 Week High | $4.60 | |||
| Open | $0.62 | 52 Week Low | $2.81 | |||
| Day High | $0.67 | P/E | N/A | |||
| Day Low | $0.61 | EPS | $0.00 | |||
| Volume | 519,844 | |||||
